Everolimus for the treatment of pancreatic neuroendocrine tumors

Feldmann, Georg; Schütte, Ute; Haarmann, Jens; Brossart, Peter

doi:10.1517/14656566.2012.713348

Cited by 6 publications

(2 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent years have seen significant improvements in clinically available diagnostic tools as well as therapeutic options. Namely, there is now a considerable portfolio of locally ablative approaches such as novel cytoreductive surgical techniques, radiotherapy, selective internal radiation therapy (SIRT), and focused radiotherapy as well as systemic therapeutic options, including biotherapy with interferons or somatostatin analogs (SSA), peptide receptor radionuclide therapy (PRRT), classical cytostatic chemotherapy, tyrosine kinase inhibitors as well as novel molecularly targeted approaches comprising antibodies or small molecule inhibitors among others [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

Mayer

Kiry

Yordanova

et al. 2020

International Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective. Neuroendocrine neoplasias (NENs) represent a rare and biologically heterogeneous group of malignancies. Treatment of NEN patients remains challenging due to lack of prospective evidence on the choice of ideal therapeutic sequence and therapeutic efficacy in specific individual scenarios. Methods. Clinical data on 110 consecutive patients suffering from NEN treated at a single German university center were analyzed, therapeutic regimens applied were assessed, and the outcome was evaluated. Results. Histological grading, Ki67 proliferation index, functional activity, and presence of metastases were identified as prognostic markers. 10-year overall survival rates were 92%, 44%, and 0% for G1, G2, and G3 tumors, and 60%, 39%, 69%, 53%, and 0% for Ki67 <2%, 3-5%, 6-20%, 21-49%, and >50%, respectively. Peptide receptor radionuclide therapy (PRRT) and cytostatic chemotherapy were the second most common options, with PRRT being used more frequently in NET G1 and G2 and chemotherapy in NEC G3. Combination chemotherapy with etoposide plus cisplatin or carboplatin showed disease control rates (DCRs) of overall 74%, with a short median progression-free survival (PFS) of 7 or 5 months, respectively. DCR and PFS for PRRT were 89% and 22 months when administered as monotherapy, versus 100% and 27 months upon combination with somatostatin analog (SSA) therapy. Of note, PRRT also achieved disease control as best response in 5/5 (100%) selected cases of NEC G3. Conclusion. Further prospective studies are warranted to help stratify available options for therapeutic intervention in NEN patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

Mayer

Kiry

Yordanova

et al. 2020

International Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This includes the pharmacotherapy of treatment of acid hypersecretion in ZES patients[4,11, 27,28]; a review of diagnosis of ZES[4,29–34]; general management of ZES[4,11]; surgical management of ZES[16,25,35,36] and the treatment of advanced disease in patients with ZES and other PETs or gastrointestinal NETs[36–41]. The latter include reviews of targeted therapies with mTor inhibitors[36,37,39,42,43], tyrosine kinase inhibitors[36,37,39,42], somatostatin analogues[36,37,39,44,45]; liver-directed therapies and peptide radio-receptor therapy (PRRT)[36,37,39,46–50]; surgical debulking/cytoreduction[35–37] and chemotherapy[36,37,39]. …”

Section: Introductionmentioning

confidence: 99%

Pharmacotherapy of Zollinger–Ellison syndrome

Ito

Igarashi

Uehara

et al. 2013

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction Pharmacotherapy in the management of patients with ZES is often equated with the medical management of the acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. Areas covered This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is pharmacotherapy in the control of acid hypersecretion; in controlling other hormonal hypersecretory states these patients may develop, including the hyperparathyroidism in patients with MEN1 and ZES; pharmacotherapy involved in tumor localization; and pharmacotherapy involved in the treatment of advanced metastatic disease. The latter includes chemotherapy; liver-directed therapies; biotherapy (somatostatin/interferon); peptide radio-receptor therapy; and molecular targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Expert Opinion Pharmacotherapy is now involved in all aspects of management of patients. The result of this is that ZES has progressed from where it initially was entirely a surgical disease to the present where medical treatment plays a major role in almost all aspects of the management of these patients.

show abstract

Therapeutic Antibodies in Cancer Therapy

Gasser¹,

Waaga-Gasser²

2015

Protein Targeting Compounds

View full text Add to dashboard Cite

Everolimus for the treatment of pancreatic neuroendocrine tumors

Cited by 6 publications

References 90 publications

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

Pharmacotherapy of Zollinger–Ellison syndrome

Therapeutic Antibodies in Cancer Therapy

Contact Info

Product

Resources

About